

***All Member DAEWG Meeting***

*October 17, 2014*

*12:30 - 2:00pm*

*Venue: Room E205, Annex Hall, Pacifico Yokohama*

# *Purpose & Expected Results*

***Purpose:*** *This all member DAEWG meeting is to provide an opportunity to learn of progress made since the third APAC meeting and to discuss the overall strategy and direction for the DAEWG.*

***Expected Results:*** *A shared understanding of current status of DAEWG activities and each stakeholder's role in implementing the DAEWG's strategy up to APAC 2015.*

# Agenda

- 1. Report back on day 0, day 1 and day 2 events*
- 2. Share progress of each country's activities*
- 3. Discuss how to further develop multilateral collaboration*



# Agenda

1. *Report back on day 0, day 1 and day 2 events*
2. *Share progress of each country's activities*
3. *Discuss how to further develop multilateral collaboration*

# *Day 0: Research Center Site Visit*

***Purpose:*** *This tour is to introduce APAC researchers to the capabilities of Japanese pharmaceutical companies in the research area and to promote bilateral understanding of the research being undertaken in each country.*

# *Day 0: Participants & Facilities*

***Participants:*** 26 people from Taiwan (15), Thailand (4), Malaysia (2), Korea (1), and Japan (4)

## ***Visited facilities:***


*Takeda Shonan Research Center*

*Kyowa-Kirin Tokyo Research Center*

# *Takeda Shonan Research Center*



# *Kyowa-Kirin Tokyo Research Park*





## *Day 1: Asia business development partnering conference*

***Purpose:*** *The purpose of this session is to provide an opportunity for the APAC countries to directly introduce their economy and partnering opportunities to business development representatives from pharmaceutical companies. Each country is asked to invite business development representatives to the session to promote cross-border collaborations.*

# *Day 1: Agenda*

- 1. Opening, APAC/DAEWG introduction and Japan introduction – Keisuke Watanabe*
- 2. Approach to partnering with Korea – Dongho Lee*
- 3. Approach to partnering with Malaysia – Jay Padasian*
- 4. Approach to partnering with Taiwan – Shan Chi Ku*
- 5. Approach to partnering with Thailand – Nares Damrongchai*
- 6. Japanese Pharma Introductions*
- 7. Networking*
- 8. Closing Remarks – Jun Terauchi*

# Day1: Participants

- *21 People of 13 companies from Japan*

*Merck Serono Co., Ltd., SHIONOGI & CO., LTD., Takeda Pharmaceutical Co LTD., Kowa Co., Ltd., Chugai Pharmaceutical Co., Ltd., Astellas Pharma Inc., Ono Pharmaceutical Co., Ltd., Eisai Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Co., Ltd.*

- *20 People of 15 companies and academia from outside of Japan*

*DCB (Taiwan), BPIPO (Taiwan), ITRI (Taiwan), Mycenax (Taiwan), EriGenix (Taiwan), NangKuang (Taiwan), GlycoNex Inc. (Taiwan), PPCK.K. (Taiwan), NKcompany (Taiwan), NRPB (Taiwan), Mahido University (Thailand), TCELS (Thailand), BiotechCorp Malaysia (Malaysia), Asan Medical Center (Korea), (China)*

# *Day 1: Asia business development partnering conference*



## *Day 2: Capacity building seminar*

***Purpose:*** *To share insights on how to promote drug discovery capacity building in the APAC region through open innovation.*

# Day 2: Agenda

## **Presentations** (moderator - Kentaro Yoshimatsu, Eisai)

1. *Actemra – An open innovation success story (Chugai, Japan)*
2. *Financing drug seeds and capacity development (Dr. Dongho Lee, KDDF, Korea)*
3. *Promoting an open drug discovery platform (Dr. Wei-Kuang Chi, DCB, Taiwan)*
4. *Developing a new drug discovery capacity (Dr. Nares Damrongchai TCELS, Thailand)*
5. *Developing global researchers in drug discovery (Prof. Hiroko Isoda, Tsukuba University, Japan)*

## **Panel discussion** (moderator: Kentaro Yoshimatsu, Eisai)

- ✓ *Understanding the role of open innovation and collaborations in capacity building*
- ✓ *Understanding the role of investment and exit strategies in order to promote drug discovery*
- ✓ *Understanding the open innovation mindset to capacity building*
- ✓ *Understanding the government commitment to developing a drug discovery capacity*
- ✓ *Understanding the issues in developing researcher capacity*

## *Day 2: Capacity building seminar*




# Agenda

- 1. Report back on day 0, day 1 and day 2 events*
- 2. Share progress of each country's activities*
- 3. Discuss how to further develop multilateral collaboration*



# The current status of progress in DAEWG

As of Sep.4, 2014



***Implement open innovation through the platform!***

# The current status of progress in DAEWG

As of Sep.4, 2014



- In China, SINO-PhIRDA has joined as a new DAEWG member in China through direct visit to Beijing in last month
- With Malaysia, we are communicating regarding delegation in December
- With Hong-Kong, we are considering how we could conduct our bilateral activity from now.

Final Step

*Implement open innovation through the platform!*

# The current status of progress in DAEWG

As of Sep.4, 2014




- For Taiwan, March 2013 / July 2014 in Bio Taiwan
- For Thailand, November 2013
- For Korea, May 2014

*Implement open innovation through the platform!*

# The current status of progress in DAEWG

As of Sep.4, 2014



➤ Day2 event participant

Taiwan, Korea Thailand, Malaysia, China, Singapore, India

*Implement open innovation through the platform!*

# The current status of progress in DAEWG

As of Sep.4, 2014



- Trial for DSAN-system in Taiwan

*Final Step*

- Plan for implementing Biz meeting in Bio Taiwan

*Implement open innovation through the platform!*

# Latest member list in DAEWG

	Japan	South Korea	Taiwan	China	Hong-Kong	Singapore	Malaysia	Thailand	India
									
International R&D type Association	JPMA	KRPIA	IRPMA	RDPAC	HKAPI	SAPI	PhAMA	PreMA	OPPI
Domestic R&D type Association		KPMA	TRPMA	SINO PhIRDA					
National Research Institute	(OCCI)	KDDF	DCB	SIMM		EDB	BIOTECH CORP	TCELS	NCBS
Academia			Academia Sinica		HKU pharmacy programm				

# Agenda

- 1. Report back on day 0, day 1 and day 2 events*
- 2. Share progress of each country's activities*
- 3. Discuss how to further develop multilateral collaboration*

## The way in developing multi-lateral activity

- Involve other countries at bilateral event
  - Taiwan meeting in Bio Japan 2013
  - ⇒ Multilateral meeting Bio Japan 2014 (Day2)
- Set the universal rule during bilateral activity and deploy other countries
  - Conduct a trial for DSAN system in Taiwan




# Roadmap for DAEWG's activities

As of Oct.6.2014

Platform Structure	From Bilateral to Multilateral				Integrated	
	(FY) 2014	2015	2016	'17-'19	2020	2025
Information sharing system (DSANA)	← Taiwan trial →				Established DSANA	●
Networking opportunity in Bio Japan					●	→
Capacity building	→					
IMI Asia	→				Established	→
DAEWG activity in APAC	←				Dissolve	

● Realization point of Asia originating drug




# Schedule for our activities in FY2014

# Progress for annual Activities in FY 2014

As of Sep.12, 2014

	May	Jun.	Jul.	Aug.	Sep.	Oct.	Nov.	Dec.	Jan.	Feb.	Mar.	Apr.
China			Bilateral Meeting		Visit	All Member meeting / Bio Japan		Bilateral Meeting			All Member tele-conference	
Hong Kong				Bilateral Meeting				Bilateral Meeting				
India					Bilateral Meeting			Bilateral Meeting				
Korea	Bio Korea	Bilateral Meeting			Bilateral Meeting			Bilateral Meeting				
Malaysia		Bilateral Meeting						Delegation	Bilateral Meeting			
Singapore								Bilateral Meeting				
Taiwan		Bilateral Meeting	Bio Taiwan		Bilateral Meeting			Bilateral Meeting				
Thailand		Bilateral Meeting						Bilateral meeting				
												4 <sup>th</sup> APAC



*We appreciate  
your cooperation  
at BioJapan 2014.*